Letter to the Editor: The Kynurenine Pathway in Hepatic Cirrhosis
Abdulla Badawy – 29 April 2019
Abdulla Badawy – 29 April 2019
Jesus Prieto, Gloria Gonzalez‐Aseguinolaza – 26 April 2019
This session will cover principles of imaging characteristics of benign and malignant hepatic lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data System (LI-RADs) for imaging findings in liver lesions and common biomarkers associated with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .
Alberto Ferrarese, Alessandro Vitale, Dino Sgarabotto, Francesco Paolo Russo, Giacomo Germani, Martina Gambato, Anna Maria Cattelan, Paolo Angeli, Umberto Cillo, Patrizia Burra, Marco Senzolo – 25 April 2019 – Bacterial infection (BI) is a major cause of worsening of liver function and death in patients with cirrhosis who are awaiting liver transplantation (LT). This study aimed to evaluate the outcome of LT candidates after a first episode of BI between January 2006 and December 2014 at Padua University Hospital.
Reina Sasaki, Subhayan Sur, Qi Cheng, Robert Steele, Ratna B. Ray – 25 April 2019 – Chronic hepatitis C virus (HCV) infection often leads to end‐stage liver disease, including hepatocellular carcinoma (HCC). We have previously observed reduced expression of microRNA‐30e (miR‐30e) in the liver tissues and sera of patients with HCV‐associated HCC, although biological functions remain unknown. In this study, we demonstrated that HCV infection of hepatocytes transcriptionally reduces miR‐30e expression by modulating CCAAT/enhancer binding protein β.
Vasantha L. Kolachala, Sirish K. Palle, Ming Shen, Asha Shenoi, Dmitry M. Shayakhmetov, Nitika A. Gupta – 25 April 2019 – Current understanding is that receptor interacting serine/threonine protein kinase 1 (RIPK1) can lead to two distinct forms of cell death: RIPK3‐mediated necroptosis or caspase 8 (Casp8)‐mediated apoptosis. Here, we report that RIPK1 signaling is indispensable for protection from hepatocellular injury in a steatotic liver undergoing ischemia reperfusion injury (IRI) but not in the lean liver.
George V. Mazariegos, Abhinav Humar – 25 April 2019
Paolo Magistri, Tiziana Olivieri, Giacomo Assirati, Gian Piero Guerrini, Roberto Ballarin, Giuseppe Tarantino, Fabrizio Benedetto – 25 April 2019
Sotiria Bedreli, Katja Straub, Anne Achterfeld, Katharina Willuweit, Antonios Katsounas, Fuat Saner, Heiner Wedemeyer, Kerstin Herzer – 25 April 2019 – Everolimus (EVR) is a mammalian target of rapamycin (mTOR) inhibitor commonly used for immunosuppression (IS) after liver transplantation (LT). However, there are concerns about whether mTOR inhibitors may move the hemostatic balance toward a higher likelihood of thrombosis. The present study aimed to investigate potential coagulation disorders after the administration of EVR.
Nedim Hadžić – 25 April 2019